Focuses on developing novel stem cell-based oncolytic virotherapies for cancer treatment.
Calidi Biotherapeutics, Inc., a clinical-stage immuno-oncology company based in San Diego, California, is dedicated to advancing allogeneic stem cell-based platforms designed to enhance and deliver oncolytic viruses for the treatment of cancer patients across the United States.
The company's robust product pipeline includes several promising candidates. CLD-101 is currently undergoing phase 1b clinical trials targeting high-grade glioma, while CLD-102 is in phase 1 trials for recurrent high-grade glioma. Additionally, CLD-201 is in preclinical trials for treating advanced solid tumors such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma. CLD-400 is also in preclinical development for lung cancer and metastatic solid tumors.
Calidi Biotherapeutics distinguishes itself with its innovative NeuroNova and SuperNova platforms, which underpin its novel approaches to delivering potent oncolytic virotherapies. These platforms represent the company's commitment to pioneering new avenues in immuno-oncology, aiming to significantly impact the treatment landscape for cancer patients worldwide.